| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Corp. &Bus. Dev. Ofcr
1 company
Doyle Janeen Noel is a Chief Corp. &Bus. Dev. Ofcr at Janux Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 1 sell.
Estimated insider holdings value: $1.0M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | JANX Janux Therapeutics, Inc. | Chief Corp. &Bus. Dev. Ofcr | Sell | 4,059 | $14.03 | $56,943.71 | -5.1% |